Clinical Trials Logo
  1. Home
  2. Neisseria Meningitidis
  3. NCT00197795

Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

Neisseria Meningitidis Clinical Trial

Clinical Trial Summary

To measure the serum bactericidal antibody levels and cell mediated immune responses before and six weeks after each dose of meningococcal outer membrane vesicle vaccine given at 0,6 and 12 weeks to healthy UK adults.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00197795
Study type Interventional
Source Public Health England
Contact
Status Completed
Phase Phase 2
Start date January 2005
Completion date December 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT01218451 - NeisVac-C Single Prime Study in Infants Phase 3
Completed NCT00323050 - Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects Phase 3
Completed NCT01090453 - Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Phase 2
Completed NCT00454987 - Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Phase 4
Completed NCT00891176 - Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Phase 3
Completed NCT01839188 - Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) Phase 3
Completed NCT01553279 - Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Phase 3
Completed NCT00263653 - Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 Phase 3
Completed NCT00772070 - Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Phase 2
Completed NCT00129116 - 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Phase 2
Completed NCT00127855 - Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine Phase 2
Completed NCT00871338 - Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Phase 2
Completed NCT00700635 - Dose Comparison Study of Menactra® in US Children Phase 2
Completed NCT00326118 - Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Phase 3
Completed NCT01730391 - Neisseria Meningitidis Burden of Disease Study N/A
Completed NCT00289783 - Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Phase 3
Completed NCT00444951 - Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia Phase 3
Completed NCT00258700 - Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Phase 3
Completed NCT03419533 - Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
Completed NCT01978093 - Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Phase 3